Moreover, a retrospective study conducted by the Okayama Liver group on HCC patients treated with Sorafenib found that VEGF levels were increased in patients who later experienced disease progression vs. non-disease progression [123]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.